<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741806</url>
  </required_header>
  <id_info>
    <org_study_id>GHB-CS03</org_study_id>
    <secondary_id>EudraCT 2007-003219-29</secondary_id>
    <nct_id>NCT00741806</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults</brief_title>
  <acronym>GHB-CS03</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVIR Green Hills Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AVIR Green Hills Biotechnology AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the hypothesis of this study that intranasal vaccination with a single dose of GHB04L1&#xD;
      is safe and induces an immune response against influenza A H5N1. This hypothesis will be&#xD;
      tested in a randomized, double-blind, placebo-controlled, Phase I dose-escalation study&#xD;
      assessing the safety and tolerability of single dose administration of GHB04L1 in healthy&#xD;
      adults. Furthermore, the local and systemic immune response as well as the pharmacokinetic&#xD;
      properties of a single dose of GHB04L1 will be studied as secondary objectives. GHB04L1 will&#xD;
      be escalated according to a fixed dose escalation scheme comprising three dose levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of GHB04L1 administered as single dose intranasal aerosol for vaccination against influenza A (H5N1) virus.</measure>
    <time_frame>study medication administration until 30 days after end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess local immune response, systemic immune response and pharmacokinetics (shedding) of a single dose of GHB04L1 aerosol administered intranasally.</measure>
    <time_frame>day1 until day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GHB04L1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPGN buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GHB04L1</intervention_name>
    <description>single dose intranasal administration of GHB04L1</description>
    <arm_group_label>GHB04L1</arm_group_label>
    <other_name>A/Vietnam/1203/04 (H5N1)-ΔNS1 virus reassortant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SPGN buffer</description>
    <arm_group_label>SPGN buffer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers, 18-50 years&#xD;
&#xD;
          -  Seronegative for H5N1&#xD;
&#xD;
          -  Seronegative for H1N1 (with antibody titers ≤1:20)&#xD;
&#xD;
          -  Written informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute febrile illness&#xD;
&#xD;
          -  Signs of acute or chronic upper or lower tract respiratory illnesses&#xD;
&#xD;
          -  History of severe atopy&#xD;
&#xD;
          -  Seasonal influenza vaccination from 2006/2007 onwards and/or pandemic influenza&#xD;
             vaccination against H5N1&#xD;
&#xD;
          -  Known increased tendency of nose bleeding&#xD;
&#xD;
          -  Volunteers with clinically relevant abnormal paranasal anatomy&#xD;
&#xD;
          -  Volunteers with clinically relevant abnormal laboratory values&#xD;
&#xD;
          -  Simultaneous treatment with immunosuppressive drugs&#xD;
&#xD;
          -  Clinically relevant history of renal, hepatic, GI, cardiovascular,haematological,&#xD;
             skin, endocrine, neurological or immunological diseases&#xD;
&#xD;
          -  History of leukaemia or cancer&#xD;
&#xD;
          -  HIV or Hepatitis B or C seropositivity&#xD;
&#xD;
          -  Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic&#xD;
             injury of the nose within 30 days prior to application of study medication&#xD;
&#xD;
          -  Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood&#xD;
             transfusions, or an investigational drug within four weeks prior to study medication&#xD;
             application&#xD;
&#xD;
          -  Volunteers who have received anti-inflammatory drugs 2 days prior to study medication&#xD;
             application&#xD;
&#xD;
          -  Volunteers who are not likely to cope with the requirements of the study or with a&#xD;
             significant physical or mental condition that may interfere with the completion of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Wacheck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Clinical Pharmacology, Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>March 1, 2010</last_update_submitted>
  <last_update_submitted_qc>March 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>AVIR Green Hills Biotechnology AG</name_title>
    <organization>AVIR Green Hills Biotechnology AG</organization>
  </responsible_party>
  <keyword>vaccination</keyword>
  <keyword>avian</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

